ESMO

Read news on ESMO with our app.

Read more in the app

Insilico Medicine to present first-in-human data for AI-designed pan-TEAD inhibitor ISM6331 at ESMO 2026

ESMO launches funding program for academic studies aimed at optimizing cancer care pathways

Insilico Medicine announces oral presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in mesothelioma and advanced solid tumors - EurekAlert!

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma - EurekAlert!

ESMO: 10-year survival data for lung cancer immunotherapy, new PSMA-targeted therapy for recurrent prostate cancer, promising results in metastatic colorectal and urothelial cancers - EurekAlert!

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy - EurekAlert!

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients - EurekAlert!

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients - EurekAlert!

ESMO 2025: A glimpse into the congress program - EurekAlert!

ESMO Gynaecological Cancers Congress 2025: Event announcement - EurekAlert!

ESMO releases version 2.0 of the Magnitude of Clinical Benefit Scale - EurekAlert!

SOPHiA GENETICS presents ground-breaking multimodal research on AI-driven patient stratification at ESMO 2024 - EurekAlert

ESMO: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial - EurekAlert

SOPHiA GENETICS announces poster presentations at ESMO 2024 - EurekAlert